Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

871
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
871
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

37
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

30
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
30
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

19
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
19
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Confounder in Plain Sight: A Retrospective Pilot Analysis on the Impact of Comorbidity on C-Reactive Protein Utility for Differentiating Bacterial vs. Viral Infections.

Antibiotics (Basel, Switzerland)ยท2026
Same author

Assessing the "Optimism-Knowledge Gap": An Exploratory Study of AI Awareness, Application, and Educational Needs Among a Sample of Italian Clinicians.

Healthcare (Basel, Switzerland)ยท2026
Same author

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): An Immunopathogenic Model of Dysregulated Vaccine-Triggered Immunity.

Vaccinesยท2026
Same author

Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study.

ESC heart failureยท2026
Same author

The Platelet-Virus Axis in Human Disease.

Virusesยท2026
Same author

Direct Oral Anti-Xa Anticoagulants and the Future of Factor XI/FXIa Inhibition: A New Paradigm in Thrombosis Prevention.

Pharmacy (Basel, Switzerland)ยท2026

Related Experiment Video

Updated: Sep 3, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K

Special Issue "COVID-19 and Thrombosis".

Pierpaolo Di Micco1, Egidio Imbalzano2, Giuseppe Camporese3

  • 1Uoc Medicina, P.O. A. Rizzoli-Asl Na2 Nord, Lacco Ameno, 80076 Naples, Italy.

Viruses
|July 27, 2022
PubMed
Summary

The study found a link between COVID-19 and venous thromboembolism, especially in hospitalized patients. This highlights the importance of monitoring blood clot risks in those with the virus.

More Related Videos

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

680
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K

Related Experiment Videos

Last Updated: Sep 3, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K
Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

680
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases

Background:

  • The ongoing COVID-19 pandemic has seen numerous reports associating the viral infection with venous thromboembolism (VTE).
  • This association appears particularly pronounced in patients requiring hospitalization.

Discussion:

  • Understanding the mechanisms linking SARS-CoV-2 infection to VTE is crucial for effective patient management.
  • Investigating pre-existing risk factors and inflammatory responses in COVID-19 patients may elucidate VTE development.

Key Insights:

  • COVID-19 infection is significantly associated with an increased risk of venous thromboembolism.
  • Hospitalized COVID-19 patients represent a high-risk group for developing VTE.
  • Further research is needed to fully understand the pathophysiology and implement targeted preventative strategies.

Outlook:

  • Continued surveillance for VTE in COVID-19 patients is warranted.
  • Development of novel therapeutic and prophylactic strategies targeting COVID-19-associated VTE is essential.
  • Long-term studies may reveal persistent risks of VTE post-COVID-19 recovery.